Mitochondria regulate many processes that are altered in cancer cells, from metabolism to oxidative stress to apoptosis. The metabolic reprogramming in cancer cells promotes an immunosuppressive environment that drives cancer progression. However, in a recent study, researchers from the Salk Institute of Biological Sciences have identified succinate as a metabolite that accumulated due to specific disturbances in the mitochondrial electron transport chain.
Debiopharm SA has entered into an exclusive option and license agreement with Sunrock Biopharma SL to advance the development of specifically targeted antibodies.
Replay Holdings LLC has announced a research collaboration between Jura Bio Inc. and Syena, a cell therapy product company launched by Replay and the University of Texas MD Anderson Cancer Center earlier this year, to develop T-cell receptor (TCR)-based therapies.
A new method of CAR T-cell immunotherapy developed by researchers at the University of Pennsylvania Perelman School of Medicine could serve as a treatment for most blood cancers. Until now, CAR T-based immunotherapy for hematological malignancies has targeted the antigens CD19 for B cells, CD7 for T cells, BCMA for myeloma, and CD33 for AML.
Leucid Bio Ltd. has received approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to commence a phase I/II trial of LEU-011 for the treatment of adults with relapsed or refractory solid tumors.
Tegid Therapeutics Inc. has identified proteolysis targeting chimera (PROTACs) compounds comprising cereblon (CRBN) ligands covalently bonded to a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1)-targeting moiety.
Researchers from Huazhong University of Science and Technology presented the discovery and preclinical evaluation of a novel peptide PET tracer targeting LAG-3, [68Ga]NOTA-XH05, being developed as a candidate for evaluating the efficacy of cancer immunotherapy.
U3-1402/patritumab-GGFG-DXd is the first HER3-targeting antibody-drug conjugate (ADC) showing clinical efficacy in non-small-cell lung cancer. However, an elevated proportion of patients with this cancer express low levels of HER3 and are nonresponsive to this ADC. In addition, novel ADCs are needed to treat other cancer types, including colorectal cancer.
Pharmabcine Inc. has received approval from the human research ethics committee (HREC) in Australia for a phase Ia/b trial of PMC-309, a monoclonal antibody against the human V-domain Ig suppressor of T-cell activation (VISTA) ligand.
RSS
